Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Arteriosclerosis Obliterans D001162 8 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Arthus Reaction D001183 8 associated lipids
Ascites D001201 25 associated lipids
Asthenia D001247 5 associated lipids
Asthma D001249 52 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Montalescot G et al. Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries. 1990 Am. Heart J. pmid:2248190
Tomoda H Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). 1986 Am. Heart J. pmid:3532743
Walinsky P et al. Thromboxane A2 in acute myocardial infarction. 1984 Am. Heart J. pmid:6485997
O'Connor KM et al. Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. 1986 Am. Heart J. pmid:3953390
Austin JC et al. Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion. 1988 Am. Heart J. pmid:3344655
Arora RR et al. Laser-induced stimulation of thromboxane B2 synthesis in human blood platelets: role of superoxide radicals. 1993 Am. Heart J. pmid:8381256
Cambria RA et al. Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia. 1991 Am Surg pmid:1847027
Ingster LM and Feinleib M Salicylate intake and cardiovascular disease: Ingster and Feinleib respond to Hu and Willett. 1998 Am J Public Health pmid:9702172
Satterfield S et al. Biochemical markers of compliance in the Physicians' Health Study. 1990 Sep-Oct Am J Prev Med pmid:2268456
Natarajan G et al. Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. 2008 Am J Perinatol pmid:18726836
Brown HL et al. Plasma and amniotic fluid prostacyclin and thromboxane in mild pregnancy-induced hypertension. 1987 Am J Perinatol pmid:3566883
Mehta P et al. Plasma concentrations of thromboxane and prostacyclin metabolites in patients with bone tumors. 1985 Am J Pediatr Hematol Oncol pmid:2994511
Jung TT and Juhn SK Prostaglandins in human cholesteatoma and granulation tissue. 1988 Am J Otol pmid:3177602
Leese PT et al. Valdecoxib does not impair platelet function. 2002 Am J Emerg Med pmid:12098171
Andersson T et al. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. 2012 Am J Cardiovasc Drugs pmid:22631032
Elissalde MH and Beier RC Stimulation and release of prostaglandins and thromboxane from macrophages by cotton dust associated lipopolysaccharides. 1990 Am Ind Hyg Assoc J pmid:2270833
Tanaka H et al. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. 1999 Allergy pmid:10380781
Oosaki R et al. Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. 1997 Allergy pmid:9188934
Mita H et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. 2001 Allergy pmid:11703219
Collins CE et al. Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. 1996 Aliment. Pharmacol. Ther. pmid:8791957
Treiber G et al. The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa. 2006 Aliment. Pharmacol. Ther. pmid:16393293
Van Hecken A et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. 2002 Aliment. Pharmacol. Ther. pmid:12197849
Cole AT et al. Low dose aspirin: selective inhibition of rectal dialysis thromboxane B2 in healthy volunteers. 1994 Aliment. Pharmacol. Ther. pmid:7865644
Carty E et al. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. 2000 Aliment. Pharmacol. Ther. pmid:10848666
Wannhoff A et al. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. 2016 Aliment. Pharmacol. Ther. pmid:26919285
Signore C et al. Markers of oxidative stress and systemic vasoconstriction in pregnant women drinking > or =48 g of alcohol per day. 2008 Alcohol. Clin. Exp. Res. pmid:18715278
Siler-Khodr TM et al. Effect of ethanol on thromboxane and prostacyclin production in the human placenta. 2000 Alcohol pmid:10963940
Hillbom M et al. Effects of ethanol on platelet function. 1985 May-Jun Alcohol pmid:4026960
Shalina RI et al. [Synthesis of prostaglandins and lipid peroxidation in pregnant women with gestosis]. 1988 Akush Ginekol (Mosk) pmid:3213902
Bashakin NF et al. [The functional characteristics of the prostacyclin-thromboxane system in newborn infants with a history of acute and chronic intrauterine hypoxia]. 1993 Akush Ginekol (Mosk) pmid:8311150
Fernández-Cruz E et al. Increased synthesis and production of prostaglandin E2 by monocytes from drug addicts with AIDS. 1989 AIDS pmid:2496725
Patrono C et al. Radioimmunoassay measurement of stable metabolites of platelet arachidonic acid: a convenient method for the in vitro and ex vivo evaluation of cyclo-oxygenase inhibitors. 1980 Agents Actions Suppl. pmid:6787852
Patrono C et al. Inhibition of platelet cyclooxygenase by aspirin-like drugs: methods for in vitro and ex vivo assessment. 1979 Agents Actions Suppl. pmid:115255
Chignard M et al. Arachidonate-mediated bronchoconstriction and platelet activation are inhibited by microgram doses of compound L8027 which are not selective for thromboxane synthetase. 1979 Agents Actions Suppl. pmid:291306
Peskar BA and Holland A Plasma levels of immunoreactive 15-keto-13,14-dihydro-thromboxane B2 in guinea pigs during anaphylaxis and after histamine injection. 1979 Agents Actions Suppl. pmid:294148
Cerletti C et al. Comparison of the effects of oral and intravenous aspirin administration on platelet and peripheral vascular cyclo-oxygenase activity: studies in rats and in man. 1986 Agents Actions Suppl. pmid:3101444
Mihai K et al. Association between total cholesterol and thromboxane B2 levels in offspring of parents suffering from premature coronary artery disease. 1992 Agents Actions Suppl. pmid:1632293
Petö J et al. Association between total cholesterol and plasma thromboxane B2 in human adults. 1992 Agents Actions Suppl. pmid:1632296
Mentz P and Giessler C Biosynthesis of TXB2 and 6-oxo-PGF1 alpha in the heart and other tissues under pathophysiological conditions. 1992 Agents Actions Suppl. pmid:1632315
Ghanem NS et al. The cardiac and renal effects of the complement fragment C5a des Arg are partly mediated by the release of histamine and arachidonic acid metabolites. 1989 Agents Actions pmid:2473617
De Clerck F et al. Platelet activation by endogenous 5-hydroxytryptamine and histamine released by mast cell degranulation with compound 48/80 in the rat. 1983 Agents Actions pmid:6858790
Nosál R et al. Antihistaminic drug bromadryl and stimulated platelet aggregation. 1994 Agents Actions pmid:7976789
Zatta A et al. At low extracellular calcium concentration platelet activating factor induces beta-thromboglobulin release from human platelets through thromboxane-endoperoxides formation. 1987 Agents Actions pmid:2961218
de Clerck F et al. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist. 1982 Agents Actions pmid:6215842
de Clerck F et al. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41,468), a selective 5-HT2-receptor antagonist. 1982. 1994 Agents Actions pmid:7725978
Cifone MG et al. Stimulatory effect of hr tumor necrosis factor on TxB2 release by polymorphonuclears and macrophages. 1986 Agents Actions pmid:3825754
Carr DP et al. Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of non-steroidal anti-inflammatory drugs in the rat. 1986 Agents Actions pmid:3825757
Berti F et al. Immune release of histamine and other lipid mediators from guinea-pig isolated kidney: antagonism by BN-52021. 1990 Agents Actions pmid:1696776
Nosál R et al. Effect of chloroquine on isolated mast cells. 1991 Agents Actions pmid:1716835
Conti P et al. Effect of supernatants from PHA-stimulated and non-stimulated lymphocyte cultures on thromboxane B2 release by polymorphonuclear leukocytes in vitro. 1985 Agents Actions pmid:4003201